Psoriatic Arthritis – Unmet Need – Detailed, Expanded Analysis (US & EU)
For the abstract please provide an overview paragraph here and then fill in the bulleted sections below. Feel free to modify the bulleted section. Leverage content from a brochure if you have one.
Although tumor necrosis factor-alpha (TNF-α) inhibitors remain the preferred treatments for psoriatic arthritis (PsA) following failure of conventional disease-modifying antirheumatic drugs (cDMARDs), the more recently introduced interleukin-17 (IL-17) inhibitors Cosentyx and Taltz and the oral therapies Otezla and Xeljanz have chipped away at TNF-α inhibitors’ patient share. Understanding the underlying unmet need in the treatment of PsA, as well as the factors that can differentiate similar products from one another, can determine the success of an agent in this competitive space. This report presents the unmet needs in PsA treatment based on the results of surveys of U.S. and European rheumatologists and dermatologists and provides the tools to make strategic decisions and assessments regarding the PsA therapy market.
QUESTIONS ANSWERED
- How do Novartis’s Cosentyx, Eli Lilly’s Taltz, Amgen’s Otezla, and Pfizer’s Xeljanz compare with other agents for PsA in terms of efficacy, safety, convenience of administration, and access to reimbursement?
- How do American College of Rheumatology (ACR) response, Psoriasis Area and Severity Index (PASI) score, Health Assessment Questionnaire-Disability Index (HAQ-DI) improvement, risk of malignancy, and rate of infection affect rheumatologists’ and dermatologists’ prescribing decisions for PsA?
- How do U.S. and European rheumatologists and dermatologists view the value of oral therapies for PsA?
- What are the prevailing areas of unmet need and opportunity in the PsA market?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by our experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 62 U.S. and 30 European rheumatologists and dermatologists fielded in January 2021
Key companies: AbbVie, Amgen, Pfizer, Janssen, Novartis, Eli Lilly
Key drugs: Humira, Enbrel, Stelara, Cosentyx, Taltz, Otezla, Xeljanz
Table of contents
- Psoriatic Arthritis - Unmet Need - Detailed, Expanded Analysis (US & EU)
- Executive Summary
- Unmet Need - Psoriatic Arthritis - Executive Summary - April 2021
- Introduction
- Overview
- Methodology
- Rationale for Treatment Drivers and Goals Selection
- Rationale for Drug Selection
- Products for Psoriatic Arthritis and Rationale for Drug Selection
- Treatment Drivers and Goals
- Key Findings: Attribute Importance
- Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Rheumatologists' and Dermatologists' Prescribing Decisions in Psoriatic Arthritis
- Importance of Efficacy Attributes to Prescribing Decisions in Psoriatic Arthritis: United States
- Importance of Efficacy Attributes to Prescribing Decisions in Psoriatic Arthritis: Europe
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in Psoriatic Arthritis: United States
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in Psoriatic Arthritis: Europe
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Psoriatic Arthritis: United States
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Psoriatic Arthritis: Europe
- Importance of Nonclinical Factors to Prescribing Decisions in Psoriatic Arthritis: United States
- Importance of Nonclinical Factors to Prescribing Decisions in Psoriatic Arthritis: Europe
- Key Findings: Stated vs. Derived Importance
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Psoriatic Arthritis: United States
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Psoriatic Arthritis: Europe
- Product Performance Against Treatment Drivers and Goals
- Key Findings
- Overall Performance of Key Therapies for Psoriatic Arthritis: United States
- Overall Performance of Key Therapies for Psoriatic Arthritis: Europe
- Mean Overall Performance of Key Therapies for Psoriatic Arthritis: United States and Europe
- Relative Performance of Key Therapies for Psoriatic Arthritis Across Select Efficacy Attributes: United States
- Relative Performance of Key Therapies for Psoriatic Arthritis Across Select Efficacy Attributes: Europe
- Relative Performance of Key Therapies for Psoriatic Arthritis Across Select Safety and Tolerability Attributes: United States
- Relative Performance of Key Therapies for Psoriatic Arthritis Across Select Safety and Tolerability Attributes: Europe
- Relative Performance of Key Therapies for Psoriatic Arthritis Across Select Convenience of Administration Attributes: United States
- Relative Performance of Key Therapies for Psoriatic Arthritis Across Select Convenience of Administration Attributes: Europe
- Relative Performance of Key Therapies for Psoriatic Arthritis Across Select Nonclinical Attributes: United States
- Relative Performance of Key Therapies for Psoriatic Arthritis Across Select Nonclinical Attributes: Europe
- Assessment of Unmet Need
- Key Findings: Unmet Need in Psoriatic Arthritis
- Surveyed Rheumatologistsu2019 and Dermatologists' Satisfaction with the Performance of Key Therapies for Psoriatic Arthritis on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
- Surveyed Rheumatologistsu2019 and Dermatologists' Satisfaction with the Performance of Key Therapies for Psoriatic Arthritis on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
- Surveyed Rheumatologistsu2019 and Dermatologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Psoriatic Arthritis: United States
- Surveyed Rheumatologistsu2019 and Dermatologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Psoriatic Arthritis: Europe
- Surveyed Rheumatologistsu2019 and Dermatologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Psoriatic Arthritis: United States
- Surveyed Rheumatologistsu2019 and Dermatologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Psoriatic Arthritis: Europe
- Surveyed Rheumatologistsu2019 and Dermatologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Psoriatic Arthritis: United States
- Surveyed Rheumatologistsu2019 and Dermatologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Psoriatic Arthritis: Europe
- Surveyed Rheumatologistsu2019 and Dermatologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Psoriatic Arthritis: United States
- Surveyed Rheumatologistsu2019 and Dermatologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Psoriatic Arthritis: Europe
- Key Findings: Unmet Need in Psoriatic Arthritis and Related Indications
- Surveyed Rheumatologistsu2019 and Dermatologists' Ascribed Level of Unmet Need in Psoriatic Arthritis and Related Indications: United States
- Surveyed Rheumatologistsu2019 and Dermatologists' Ascribed Level of Unmet Need in Psoriatic Arthritis and Related Indications: Europe
- Opportunity Analysis
- Areas of Opportunity in the PsA Market and Emerging Therapy Insights
- Opportunity: A More-Efficacious Oral Targeted Synthetic DMARD
- Opportunity: An Agent That Is More Efficacious in Reducing Musculoskeletal Disease Activity
- Opportunity: Therapies with a Novel Mechanism of Action
- Areas of Opportunity in the PsA Market and Emerging Therapy Insights
- Target Product Profiles
- Assessing Drug Development Opportunities
- Target Product Profile Methodology
- Attributes and Attribute Levels
- Attribute Importance and Part-Worth Utilities
- PsA Target Product Profile: Attribute Importance
- ACR 50 Response at Week 24 (% of Patients, Placebo-Adjusted)
- PASI 75 Response at Week 24 (% of Patients, Placebo-Adjusted)
- Decrease in HAQ-DI Score at Week 24 (Baseline-Normalized, Placebo-Adjusted)
- Medication Possession Ratio
- Malignancy Warning from the FDA
- Rate of Serious Infections (per 100 Patient-Years, Placebo-Adjusted)
- Price per Day (Relative to Humira)
- Conjoint Analysis-Based Simulation of a Market Scenario
- PsA Market Simulation: Share of Preference of Target Product Profiles Included in the Market Scenario
- PsA Market Simulation: Likelihood to Prescribe Target Product Profiles Included in the Market Scenario
- PsA Market Simulation: Target Product Profiles Included in the Market Scenario
- Appendix
- Key Abbreviations
- Experts Interviewed
- Bibliography
- Executive Summary
Swati Kinger, M.B.A., is an analyst on the Immune and Inflammatory Disorders team at Clarivate. Previously, she was an associate consultant for a life sciences firm, where she worked on syndicated offerings and ad-hoc requests involving patient journeys, market assessment, and competitive intelligence. She holds a bachelor’s degree in pharmacy and an M.B.A. in pharmacy from the National Institute of Pharmaceutical Education and Research in India.